Vyome Holdings, Inc. (HIND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vyome Holdings, Inc. (HIND) has a cash flow conversion efficiency ratio of -0.124x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-903.71K) by net assets ($7.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Vyome Holdings, Inc. for the company's overall valuation and market capitalisation.
Vyome Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Vyome Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vyome Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vyome Holdings, Inc. ranked by their cash flow conversion efficiency. Explore HIND cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Equus Total Return Closed Fund
NYSE:EQS
|
0.000x |
|
Falcon Power Co Ltd
TW:1516
|
-0.050x |
|
E for L Aim Public Company Limited
BK:EFORL
|
0.042x |
|
Skillful Craftsman Education Tech
NASDAQ:EDTK
|
-0.079x |
|
Antec Inc
TWO:6276
|
-0.061x |
|
Pluri Inc.
NASDAQ:PLUR
|
0.347x |
|
Energys Group Limited Ordinary Shares
NASDAQ:ENGS
|
N/A |
|
Thanasiri Group Public Company Limited
BK:THANA
|
0.024x |
Annual Cash Flow Conversion Efficiency for Vyome Holdings, Inc. (2005–2025)
The table below shows the annual cash flow conversion efficiency of Vyome Holdings, Inc. from 2005 to 2025. View today's stock price for Vyome Holdings, Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.76 Million | $-3.75 Million | -0.997x | -105.69% |
| 2024-12-31 | $-253.00K | $-4.43 Million | 17.498x | +787.44% |
| 2023-12-31 | $6.66 Million | $-16.96 Million | -2.545x | +57.45% |
| 2022-12-31 | $3.66 Million | $-21.90 Million | -5.983x | -1625.07% |
| 2021-12-31 | $44.33 Million | $-15.38 Million | -0.347x | +41.23% |
| 2020-12-31 | $14.49 Million | $-8.55 Million | -0.590x | -0.19% |
| 2019-12-31 | $24.11 Million | $-14.20 Million | -0.589x | +32.16% |
| 2018-12-31 | $31.66 Million | $-27.49 Million | -0.868x | -169.66% |
| 2017-12-31 | $76.37 Million | $-24.59 Million | -0.322x | +95.42% |
| 2016-12-31 | $2.94 Million | $-20.66 Million | -7.028x | -14.19% |
| 2015-12-31 | $3.67 Million | $-22.61 Million | -6.155x | -111.59% |
| 2014-12-31 | $6.66 Million | $-19.38 Million | -2.909x | -131.72% |
| 2013-12-31 | $14.68 Million | $-18.43 Million | -1.255x | +33.69% |
| 2012-12-31 | $11.88 Million | $-22.48 Million | -1.893x | -90.30% |
| 2011-12-31 | $20.04 Million | $-19.94 Million | -0.995x | -116.26% |
| 2010-12-31 | $29.71 Million | $-13.66 Million | -0.460x | +89.59% |
| 2009-12-31 | $5.58 Million | $-24.66 Million | -4.418x | -49.66% |
| 2008-12-31 | $11.41 Million | $-33.67 Million | -2.952x | -472.02% |
| 2007-12-31 | $45.28 Million | $-23.37 Million | -0.516x | +9.13% |
| 2006-12-31 | $28.57 Million | $-16.23 Million | -0.568x | +89.09% |
| 2005-12-31 | $1.97 Million | $-10.28 Million | -5.205x | -- |
About Vyome Holdings, Inc.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinica… Read more